Back
Top 1%
14.9%
Top 0.1%
14.9%
Top 52%
12.0%
Top 0.6%
6.5%
#1
6.5%
Top 33%
5.1%
Top 0.6%
4.2%
Top 10%
4.2%
Top 1%
3.9%
Top 6%
2.0%
Top 80%
2.0%
Top 13%
1.6%
Top 43%
1.6%
Top 3%
1.4%
Top 11%
1.0%
Top 8%
0.7%
Top 2%
0.7%
Top 10%
0.7%
A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
2026-01-12
oncology
Title + abstract only
View on medRxiv
Show abstract
ObjectivesHead and neck cancer (HNC) has a high recurrence rate. Safety and effectiveness of PepCan in reducing recurrence for HNC patients were assessed. Methods and analysisPepCan consists of four human papillomavirus 16 (HPV 16) E6 peptides and a Candida skin testing reagent (Candin(R), Nielsen Biosciences) as a vaccine adjuvant. Since Candida was known to have a general immune stimulating effects, patients were recruited regardless of their HPV status. Men and women with HNC who had no evid...
Predicted journal destinations
1
Cancers
57 training papers
2
Frontiers in Oncology
34 training papers
3
PLOS ONE
1737 training papers
4
Clinical Cancer Research
22 training papers
5
BMC Cancer
21 training papers
6
BMJ Open
553 training papers
7
Cancer Medicine
17 training papers
8
eLife
262 training papers
9
British Journal of Cancer
22 training papers
10
Frontiers in Immunology
140 training papers
11
Scientific Reports
701 training papers
12
JAMA Network Open
125 training papers
13
Nature Communications
483 training papers
14
Diagnostics
36 training papers
15
Vaccines
131 training papers
16
PeerJ
46 training papers
17
International Journal of Cancer
18 training papers
18
Vaccine
140 training papers